



<b>Substitute for Form 1449/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/511,016
				Filing Date	May 31, 2005
				First Named Inventor:	Dong-Hyun Kim
				Art Unit	1655
				Examiner Name	Clark, Amy Lynn
Sheet	2	of	2	Attorney Docket Number	8483P002
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		H. Hasegawa, et al., "Main ginseng saponin metabolites formed by intestinal bacteria," Planta Med., Vol. 62, No. 5, pp. 435-437 (October 1996)			
		Costantino Iadecola, et al., "Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice," Proceedings of the National Academy of Sciences, Vol. 98, No. 3, pp. 1294-1299 (January 30, 2001)			
		Hye-Young Park, et al., "Inhibitory Effects of Bifidobacterium Spp. Isolated from a Healthy Korean on Harmful Enzymes of Human Intestinal Microflora," Archives of Pharmacal Research, Vol. 21, No. 1, pp. 54-61 (1988)			
		Eun-Ah Bae, et al., "Constitutive $\beta$ -Glucosidases Hydrolyzing Ginsenoside Rb1 and Rb2 from Human Intestinal Bacteria," Biol. Pharm. Bull., Vol. 23, pp. 1481-1485 (2000)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.